A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Renal Hemodynamic Effects of RLX030 and Placebo Infused for 24 Hours in Subjects With Chronic Heart Failure (CHF).
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2014
At a glance
- Drugs Serelaxin (Primary)
- Indications Chronic heart failure
- Focus Pharmacodynamics
- Sponsors Novartis
- 07 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Mar 2012 New source identified and integrated (European Clinical Trials Database).
- 14 Mar 2012 New trial record